Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 4/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 10/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9955801 | 0.93 | HDAC1 (0.44) | CSNK1DCSNK1EHDAC1HDAC8HDAC6 | |
| SCHEMBL9955567 | 0.92 | CSNK1D (0.41) | CSNK1DCSNK1EHDAC1RIPK1LMNA | |
| SCHEMBL9957158 | 0.90 | POLB (0.37) | CSNK1DCSNK1ERIPK1MAPT | |
| SCHEMBL10277152 | 0.88 | CSNK1D (0.40) | CSNK1DCSNK1ERIPK1LMNAMAPT | |
| SCHEMBL10277153 | 0.88 | CSNK1D (0.40) | CSNK1DCSNK1ERIPK1LMNAMAPT | |
| SCHEMBL9957083 | 0.86 | HDAC1 (0.43) | CSNK1DCSNK1EHDAC1HDAC8HDAC6 | |
| SCHEMBL9956458 | 0.86 | CSNK1D (0.42) | CSNK1DCSNK1ERIPK1LMNAMAPT | |
| SCHEMBL9956786 | 0.86 | CSNK1D (0.42) | CSNK1DCSNK1ERIPK1LMNAMAPT | |
| SCHEMBL9957320 | 0.85 | AURKA (0.47) | CSNK1DCSNK1ERIPK1MAPT | |
| SCHEMBL9956973 | 0.83 | FYN (0.44) | CSNK1DCSNK1ERIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI (USA), LTD. | 2012-07-12 | — | — | US | claimed |
| EP-2635578-B1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI USA LTD (US) | 2015-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PRXL2A, CDK2, CCNA2 | CSNK1D 655/4885CSNK1E 852/4885PIM2 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.